Došlo je do najnovijeg otkrića u raku pluća nemalih stanica. Vrsta imunizacija koji može liječiti karcinom pluća bez malih stanica (NSCLC) doživio je kliničko odobravanje 3. stupnja i ima velik terapeudski utjecaj na bolest nemalih stanica pluća. Trenutno je dostupan u vrlo malo zemalja.
As an anti-idiotype monoclonal antibody, the vaccine enables lung cancer patients to respond strongly to specific glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with the best supportive care, lung cjepivo protiv raka može poboljšati stopu preživljenja pacijenata sa stadijem relapsa i uznapredovalim (stadij IIIB / IV) NSCLC.
Rather than numerous warm blooded creatures, including gorillas, we can’t recognize the nearness of NeuGcGM3 gangliosides in typical human tissues and liquids. Be that as it may, NeuGcGM3 gangliosides are profoundly communicated in certain human malignant growth cells. In non-little cell lung malignancy tests, gangliosides were identified in over 90% of non-little cell lung tumors. Thusly, NeuGcGM3 ganglioside can be utilized as a ground-breaking objective for lung malignant growth antibodies.
Nakon što neosjetljivi okvir stvara eksplicitna antitijela protiv antigen, može stvoriti antitijela protiv jedinstvenosti glavnog antigena, koji mogu kontrolirati otporni okvir iznutra. Nakon imunizacije protiv ovog malignog rasta pluća imunizacija, it can advance the generation of antibodies against this antigen, assigned Ab1. These Ab1 antibodies are fit for delivering a progression of hostile to idiotypic antibodies, assigned Ab2. The idiotypes of these exceptional antibodies are fused into the antigen-restricting site of Ab1, with the goal that these extraordinary antibodies produce a particular resistant reaction to regular antigens. Hence, vaccination with Ab2 immunizer can advance the creation of Ab3 (hostile to against idiotype neutralizer), and this Ab3 counter acting agent can perceive the first antigen perceived by Ab1. Some Ab2 antibodies of this sort invigorate the safe framework to actuate defensive resistance against tumor antigeni.
Klinički je dokazano da plućna bolest imunizacija je jako izdržao i ima bolje izvršenje dobrog stanja. Brojni osnovni simptomi javljaju se samo lokalno (mjesto infuzije) i uglavnom su nježni i kratke duljine. Bez obzira daje li se protutijelo pacijentima nakon raspadanja stanja, poboljšala se opća izdržljivost.
Trenutno se ova vrsta imunizacije plućnog zloćudnog rasta ne promovira u Indiji.
